

# FLUAD<sup>®</sup> QUADRIVALENT (Influenza Vaccine, Adjuvanted) included as a preferentially recommended seasonal influenza vaccine for adults 65 years and older<sup>1</sup>

For the first time, the CDC Advisory Committee on Immunization Practices (ACIP) has voted 15-0 in favor of recommending specific influenza vaccines for adults 65+.

After 2+ years of rigorous analysis, ACIP preferentially recommends the following vaccines, over standard-dose influenza vaccines<sup>1</sup>:

- Adjuvanted**  
An adjuvant is a substance added to a vaccine to boost the immune response.
- Higher dose**  
Contains a higher amount of antigen compared to standard-dose flu vaccines.

The ACIP systematic review examined **RCT and RWE data** to assess the relative benefits and harms of any higher dose or adjuvanted vaccines compared with standard-dose influenza vaccines and compared the vaccines with one another in adults 65+.<sup>2</sup>

This preferential recommendation is a significant milestone for public health as it helps provide guidance to both healthcare providers and patients on the standard of care to protect this at-risk population against influenza.<sup>1</sup>

## ACIP Recommendations for 65+<sup>1</sup>

Adults aged ≥65 years preferentially receive any one of the following **higher dose or adjuvanted** influenza vaccines\*:

- **quadrivalent high-dose inactivated influenza vaccine (HD-IIV4)**
- **quadrivalent recombinant influenza vaccine (RIV4)**
- **quadrivalent adjuvanted inactivated influenza vaccine (aIIV4)**

*If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.*

\*Adjuvanted or higher dose influenza vaccines include FLUAD<sup>®</sup> QUADRIVALENT, FLUZONE<sup>®</sup> HIGH-DOSE QUADRIVALENT, and FLUBLOK<sup>®</sup> QUADRIVALENT. CDC=Centers for Disease Control and Prevention; RCT=randomized controlled trial; RWE=real-world evidence

# Learn more about an adjuvanted influenza vaccine at [flu360.com](https://www.flu360.com)

For more information about the analysis, visit the [CDC ACIP website](https://www.cdc.gov/acip/).



## FLUAD<sup>®</sup> QUADRIVALENT (Influenza Vaccine, Adjuvanted) INDICATION and IMPORTANT SAFETY INFORMATION

### INDICATION AND USAGE

FLUAD<sup>®</sup> QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT.

### IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

Do not administer FLUAD QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

### WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

**REFERENCES:** 1. Centers for Disease Control and Prevention. ACIP Flu Meeting Update: Flu vaccines worked better than reported & ACIP recommends specific vaccines for seniors. Accessed July 6, 2022. <https://www.cdc.gov/flu/spotlights/2021-2022/specific-vaccines-seniors.htm> 2. Grohskopf L. Influenza vaccines for older adults: GRADE summary. February 23, 2022. Accessed April 6, 2022. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/04-influenza-grohskopf-508.pdf>

For US Healthcare Professional Use Only

flu360, FLUAD, FLUAD QUADRIVALENT, and WE'VE GOT FLU COVERED are registered trademarks of Seqirus UK Limited or its affiliates. All other trademarks are property of their respective owners. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2022 Seqirus USA Inc. July 2022 USA-aQIV-22-0049

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope. Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

### ADVERSE REACTIONS

The most common ( $\geq 10\%$ ) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

**To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or [www.vaers.hhs.gov](https://www.vaers.hhs.gov).**

**Before administration, please see the [full US Prescribing Information](#) for FLUAD QUADRIVALENT.**

